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Société de Réanimation de Langue Française (SRLF)Abstract
Experimental research has always been the cornerstone of pathophysiological and therapeutic advances in critical
care medicine, where clinical observations and basic research mutually fed each other in a so-called translational
approach. The objective of this review is to address the different aspects of translational research in the field of
critical care medicine. We herein highlighted some demonstrative examples including the animal-to-human
approach to study host-pathogen interactions, the human-to-animal approach for sepsis-induced immunosuppression,
the still restrictive human approach to study critical illness-related neuromyopathy, and the technological developments
to assess the microcirculatory changes in critically ill patients. These examples not only emphasize how translational
research resulted in major improvements in the comprehension of the pathophysiology of severe clinical conditions and
offered promising perspectives in critical care medicine but also point out the obstacles to translate such achievements
into clinical practice.
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Experimental research has always been the cornerstone
of pathophysiological and therapeutic advances in medi-
cine. Accurate modeling of human pathology remains
challenging but is essential to draw relevant conclusions
from experiments. With respect to critical care medi-
cine, the high mortality rate and morbidity imposed by
severe acute conditions prompted an intense research
activity in which clinical observations and experimental
research mutually fed each other in a so-called transla-
tional approach. The objective of this review is to ad-
dress the different aspects of translational research in
the field of critical care medicine. We herein highlighted
some demonstrative examples of translational research
including the animal-to-human approach to study host-
pathogen interactions, the human-to-animal approach
for sepsis-induced immunosuppression, the human-to-* Correspondence: frederic.pene@cch.aphp.fr
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in any medium, provided the original work is phuman approach to study critical illness-related neuro-
myopathy, and the technological developments to assess
the microcirculatory changes in critically ill patients. We
will not only discuss how the promises of translational
research could be fulfilled in the bedside management of
critically ill patients but also the obstacles to translate
such achievements into clinical practice.The foiled promises of host-pathogen interactions: from
animals to humans
The discovery of Toll-like receptors (TLRs) and the re-
sultant advances in the understanding of pathophysi-
ology of sepsis represent an excellent example of both
complementarities and limits of translational research.
The story began in the late nineteenth century when Elie
Metchnikoff conducted experiments on the transparent
starfish larvae in which he planted pine needles. Using a
single optical microscope, he observed a cellular infil-
trate that rapidly surrounded the foreign body with vesi-
cles of phagocytosis and described for the first time the
cellular immune response against a foreign agent [1].
For his works in innate immunity, mostly performed in
invertebrates, Metchnikoff received the Nobel Prize inOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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intense research that was prompted by the initial obser-
vation, the human receptors for pathogen molecular
patterns such as the receptor to endotoxin remained a
mystery for nine decades. The identification of TLRs as
pattern-recognition receptors (PRRs) for conserved
structures of bacteria and viruses and the acknowledge-
ment of their major roles in the inflammatory response
were made possible thanks to basic research. Indeed, a
receptor protein whose structure is very similar to TLRs
was first described in tobacco plants [2]. Two years after,
Jules Hoffmann and his group reported similar proteins
in the Drosophila fruit fly and showed that the mutation
of a receptor called Toll inhibited the production of an
antifungal peptide and increased susceptibility to fungal
infection, a discovery that was awarded by the 2011 No-
bel Prize for Medicine and Physiology. [3]. Williams
et al. also reported that Drosophila larvae carrying a
mutation on a protein of the Toll signaling pathway
(18-wheeler) had an increased susceptibility to bacterial
infections [4]. Based on these experimental results,
Medzhitov and Janeway cloned the first TLR in humans.
They confirmed the link between TLRs and the inflamma-
tory immune response by showing that transfection of a
constitutively activated TLR activated the NF-κB pathway
[5]. Following these experimental studies, numerous clin-
ical studies have confirmed the crucial role of TLR in the
immune-inflammatory response induced by infections
[6,7]. Moreover, strong associations between polymor-
phisms and mutations in TLR family members or down-
stream proteins and increased susceptibility and severity
to infections have been reported in humans [8-12].
Such findings provided a strong rationale for the de-
velopment of new therapeutic approaches based on the
modulation of the dysregulated immune response re-
sponsible for organ failures during sepsis. However,Table 1 Examples of negative human therapeutic trials target
pathophysiology of sepsis
Steps of the
inflammatory response
Target Treatment
Bacterial components Bacterial
membrane
Recombinant bactericidal
protein (rBPI21)
LPS Murine anti-endotoxin antibod
Receptors TLR-4 Lipid antagonist
of MD2-TLR4
Intracellular signaling Inflammatory
pathways
Methylprednisolone
(high doses)
Cytokine production TNF-α Soluble TNF receptor
IL-1 IL-1 receptor antagonist
Enzyme activation Phospholipase PAF inhibitor BB-882
Oxidative stress Reactive oxygen
species
Selenium
LPS, lipopolysaccharide; TLR4, Toll-like receptor 4; TNF-α, tumor necrosis factor alphexperimental animal models do not fully elucidated the
clinical conditions they aim to mimic, and both scien-
tists and physicians have raised several criticisms on the
relevance of pre-clinical experimental research based on
animal models and its translation to human pathology.
Some shortcomings are directly related to the type of
animal models of sepsis. Thus, endotoxinic shock has
often been used as a surrogate of septic shock, and ex-
perimental immunomodulatory drugs have most often
been administrated prior to or concomitant to the infec-
tious insult [13]. In addition, experimental outcomes re-
lated to a given intervention may not be consistent
across different models. For instance, attempts of tumor
necrosis factor alpha (TNFα) neutralization in experi-
mental models resulted in discrepant results, either
beneficial or detrimental, depending on the type of in-
fectious insult [14]. This skepticism was further in-
creased by the accumulation of negative human trials of
immunomodulatory drugs that had previously shown
dramatic benefits in experimental studies (Table 1).
Despite promising results in animal models, all newly
developed drugs such as anti-TNFα antibodies [15] or
the TLR4-antagonist eritoran [16] failed to improve sur-
vival to human severe sepsis and septic shock and some-
times even worsened the patient’s prognosis when using
nitric oxide synthase inhibitor or TNFα receptor:Fc fu-
sion protein [17,18].
Whether data observed in animals are really relevant to
the human conditions is certainly a major concern in med-
ical research. Discrepancies between species have been re-
cently highlighted in a study that explored the variation of
genomic response (>4,000 genes) in human and murine
blood-derived leucocytes following several types of injuries
(trauma, burn, infection) including stimulation by lipopoly-
saccharide (LPS) [19]. Changes in the gene expression pro-
file, assessed at different time points after endotoxemia,ing successive inflammatory pathways involved in the
Included population References
Meningococcal sepsis
(n = 393)
Levin et al. Lancet 2000 [76]
y Severe sepsis (n = 1,090) Angus et al. JAMA 2000 [77]
Severe sepsis (n = 1,961) Opal et al. JAMA 2013 [78]
Severe sepsis (n = 382) Bone et al. N Engl J Med 1987 [79]
Septic shock (n = 141) Fisher et al. N Engl J Med 1996 [18]
Severe sepsis (n = 696) Opal et al. Crit Care Med 1997 [80]
Severe sepsis (n = 152) Vincent et al. Crit Care Med 2000 [81]
Severe sepsis (n = 150) Valenta et al. Intensive Care Med 2011 [82]
a; IL, interleukin; PAF, platelet activating factor.
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genomic responses thereby raising an important concern
about the usefulness of mouse models in sepsis research.
However, we keep thinking that animal models remain irre-
placeable tools for advances in the field of critical care medi-
cine. The clear demonstration of ventilator-induced lung
injury in experimental animal models directly translated into
improvements in clinical care through protective ventilation
that is now applied in nearly all patients undergoing invasive
mechanical ventilation [20,21]. Should we continue to use
animal models for the purpose of drug development, the re-
producibility of any improvement in outcome should be ad-
dressed more extensively in animals with different genetic
background and underlying conditions such as age or co-
morbidities and by using various infection models. Beyond
the imperfect animal models of critical illnesses, the failure
of therapeutic clinical trials may be intrinsic to their design
as they were aimed to treat a syndrome rather than a disease
and thereby did not take into account the major heterogen-
eity of critically ill patients [22].
Sepsis-induced immunosuppression: from human to
animal and back to human
The concept of sepsis-induced immunosuppression repre-
sents a striking example of the potential of translational
research in critical care medicine. It illustrates the full vir-
tuous circle of research performed from man to mouse
and from mouse back to man, with the ultimate purpose
of developing novel therapeutic strategies.
Severe sepsis and septic shock remain associated with high
mortality rate despite advances in the management of infec-
tion and organ failures [23,24]. It is noteworthy that the ma-
jority of patients now survive the initial septic insult but
then become highly susceptible to secondary ICU-acquired
infections [25,26]. As mentioned above, anti-inflammatory
clinical trials applied at the initial phase of sepsis failed to
tackle the devastating effects of sepsis and to translate into
improved survival. This suggests that the initial patho-
physiological hypothesis may have occulted some alternative
immune changes. Furthermore, the classic paradigm of sep-
sis was dramatically challenged in the late 1990s by Richard
Hotchkiss’s pioneering works, in which post-mortem biop-
sies from patients deceased from sepsis revealed a major loss
of immune cells within lymphoid organs [27]. These
findings were reminiscent of under-recognized histor-
ical observations that were already suggestive of ac-
quired immunosuppression in septic patients, such as
unreactive skin testing owing to defective type IV hyper-
sensitivity or altered in vitro cytokine production by
monocytes, both associated with increased mortality
[28-30].
On this basis, the conception of the immune patho-
physiology of sepsis dramatically evolved and now encom-
passes both an initial tremendous systemic inflammatoryresponse responsible for organ failures and a compensa-
tory anti-inflammatory response with multiple immune
defects that may result in complex immunosuppression in
some patients [31]. The main features of sepsis-induced
immunosuppression have been recently reviewed [32]. It
is noteworthy that both innate and adaptive arms of the
immune response are seriously impaired. Since most pa-
tients survive the first days of sepsis, it has been postu-
lated that acquired immune alterations may directly
participate in a worse outcome through the inability to
clear the initial infectious focus and/or decreased resist-
ance to ICU-acquired infections. This hypothesis has been
investigated in patients in whom acquired defects in most
circulating immune cells have been strongly associated
with the outcome and the development of nosocomial in-
fections. Importantly, it is now clear that the time course
of immune defects during the ICU stay is more accurate
than the initial depth of biological abnormalities in pre-
dicting the development of ICU-acquired infections
[33-35].
A reliable appraisal of the role of sepsis-induced im-
munosuppression in clinical settings is limited by the mul-
tiple confounding risk factors of nosocomial infections.
This prompted the development of experimental research
programs aimed to mimic the common clinical situation
of severe sepsis followed by secondary infections in rodent
double-hit models. The increased susceptibility of post-
septic animals to subsequent infectious insults either to
weakly virulent pathogens or to low pathogen loads
known to be innocuous in immune-competent animals
provided a firm proof-of-concept of sepsis-induced im-
mune suppression [36,37]. These animal models allowed
the characterization of immune cells’ behavior within or-
gans, highlighted the aberrant immune response under-
lying the increased susceptibility of septic host towards a
secondary infectious insult, and are currently used to
decipher the regulatory mechanisms of sepsis-induced
immunosuppression. Such models are irreplaceable tools
to address the efficacy of potential immunomodulatory
therapeutic interventions such as cytokines (interleukin-7
(IL-7), interferon-γ (IFN-γ)), growth factors (granulocyte-
monocyte colony-stimulating factor (GM-CSF)), or cell
therapy aimed to restore an appropriate immune response
in post-septic animals. This experimental step represents
the preclinical requisite rationale before attempting
immunomodulation in septic patients.
The accumulation of clinical and experimental evi-
dence has fed the emerging idea that restoring immune
competency might represent an innovative therapeutic
target in patients during the immunosuppressive phase
of sepsis, in order to improve survival and/or to prevent
nosocomial infections (Table 2). Attempts of immune-
stimulating therapeutic interventions based on some bio-
markers of immunosuppression have been performed.
Table 2 Therapeutic targets and potential treatments of sepsis-induced immunosuppression
Biomarker Potential
therapeutics
Clinical
data
Comments
Monocyte deactivation GM-CSF Yes Restoration of HLA-DR expression [39,83]
Clearance of uncontrolled infections [83]
Reduced duration of mechanical ventilation [39]
IFN-γ Yes Restoration of HLA-DR expression [38]
Apoptosis of immune cells Anti-apoptotic
cytokines
No
Caspase inhibitors No
Death-receptor
antagonists
No
Increased Tregs Anti-Tregs antibodies No
Depletion/deactivation of
dendritic cell
Flt3-L No
TLR-agonists No
T cell exhaustion IL-7 Yes Ex vivo restoration of lymphocyte functions [40]
Thymosin-α Yes Improved survival in sepsis due to carbapenem-resistant bacteria (in association
with ulinastatin) [84]
IL-15 No
Upregulated expression of
co-inhibitory receptors
Monoclonal
antibodies:
Anti-PD1/PDL1 No
Anti-CTLA-4 No
Anti-BTLA No
GM-CSF, granulocyte-monocyte colony-stimulating factor; IFN-γ, interferon-γ; HLA-DR, human leukocyte antigen-DR; Tregs, T regulatory lymphocytes; Flt3-L, ligand of the
fms-like tyrosine kinase 3; TLR, Toll-like receptor; IL, interleukin; PD1, programmed death 1; PDL1, programmed death ligand 1; CTLA-4, cytotoxic T-lymphocyte-associated
protein 4; BTLA, B and T lymphocyte attenuator.
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GM-CSF aimed to reverse monocyte deactivation
[38,39], and new candidates are emerging from the field
of cancer such as IL-7 or anti-PD-1-related molecules
[32,40]. Such biomarker-guided therapeutic interven-
tions may represent a milestone in the development of a
personalized medicine in the ICU which is probably
more relevant to the heterogeneity of critically ill pa-
tients. Thanks to biotechnological advances, some tools
have been developed to monitor patients’ immune func-
tions in a more reproductive manner and identify those
likely to benefit from immune stimulation while minim-
izing the potential risk of harmful side effects [41,42].
Both identification of the most accurate therapeutic tar-
get and reliable immunomonitoring are keys to the
eventual success of new therapeutic interventions such
as GM-CSF and IL-7 that are currently evaluated in
clinical trials.
Critical illness-associated neuromyopathy: from human to
human
Studies of the mechanisms of critical illness-associated
neuromyopathy (CINM) illustrate how a human-to-
human translational research program can be effectivefor investigating pathological disorders and eventually
improving care [43-46]. CINM, also known as ICU-
acquired paresis or weakness, is a frequent and severe
complication of critical illness, associated with increased
mortality, delayed weaning from the ventilator, and
long-term functional disability [47-50]. CINM is clinic-
ally characterized by a bilateral and symmetric periph-
eral motor deficit, sparing cranial nerves [48]. It is most
often related to myopathy that may be associated with
sensory motor axonal polyneuropathy which signifi-
cantly worsens the functional outcome [51].
The pathophysiology of CINM is complex and encom-
passes various and intertwined mechanisms at different
stages of critical illness, from insult to recovery. Obser-
vational studies have enabled to identify risk factors of
CINM related both to the critical illness and to the ICU
management, giving clues to underlying pathogenic
mechanisms. The main factors contributing to CINM
appear to be an intense systemic inflammatory response,
unloading, malnutrition and endocrine-related anabol-
ism/catabolism imbalance, drugs (such as steroids or
neuromuscular blocking agents), and electrolyte distur-
bances [51,52]. Neurophysiological and histological in-
vestigations have been of great help for identifying the
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prognostic values of electroneuromyogram are clearly
established [48]. The observation that muscle and nerve
inexcitability was an early phenomenon predictive of
muscle weakness raised the hypothesis of a channel dys-
function that was subsequently confirmed by alternative
experiments [53]. The interest of muscle biopsy has been
remarkably demonstrated by Bradley et al. [54], by
Puthucheary et al. [46], and by Hermans et al. [43], who
thereby assessed the role of mitochondrial dysfunction,
proteolysis, and autophagy, respectively. However, the
routine applicability of muscle biopsy at the bedside re-
mains limited. Furthermore, the diaphragm is the main
respiratory muscle and is liable to early-onset injury pro-
cesses in ventilated patients but is hardly accessible for
biopsy [55,56]. Some non-invasive imaging solutions
have become of interest in order to address muscular
dysfunction in the ICU. Ultrasound imaging is a simple and
convenient tool to assess and follow up muscle atrophy.
Furthermore, magnetic resonance (MR), especially 31P, 1H,
or 13C spectroscopy, allows studying the biomechanical and
functional properties of skeletal muscle in vivo [57]. Con-
straints and risks of nerve biopsy limit the investigations in
the pathophysiology of the critical illness-associated neur-
opathy. Skin biopsy might be a convenient alternative to
nerve biopsy in order to study small-fiber neuropathy, while
advanced electrophysiological explorations may assess so-
dium channel or synaptic dysfunctions.
Hence, a ‘human-to-human’ translational research was
able to provide a comprehensive assessment of the clinical
entity of CINM and resulted in very significant insights
into the underlying pathophysiological mechanisms. Rec-
ognition of CINM is based on clinical examination, while
imaging and neurophysiological explorations can contrib-
ute to the prognosis and follow-up of the disorder. How-
ever, current therapeutic interventions for CINM remain
quite limited, based on reducing the exposure to risk fac-
tors, sustaining appropriate nutritive supply during the
ICU stay and early rehabilitation [58]. Beyond the inform-
ative but obviously limited translational research per-
formed in humans, some relevant animal models, mainly
based on experimental sepsis, are being developed in
order to further decipher the cellular and molecular
mechanisms of CINM and to allow the preclinical evalu-
ation of new therapeutics [53].
Monitoring of the microcirculation: in vivo technological
assay
Microcirculatory perfusion deals with the circulation of
blood through the small arteries, capillaries, and venules
of different tissues. This complex microvascular network
is responsible for regulation of vascular tone, adaptation
of tissue oxygenation to local metabolic demand, exchange
of nutrients and waste products between blood and cells,and regulation of immune response [59]. Experimental stud-
ies have shown that impairment in macro-hemodynamics
does not fully account for the mismatch between oxygen
demand and supply in sepsis and that pathological arterio-
venous shunt formation may also contribute to flow misdis-
tribution and eventual impairment in oxygen delivery [60].
In vivo video microscopy revealed intestinal mucosal hypo-
perfusion during murine endotoxemia. Most importantly, a
decrease in arteriolar diameters and in tissue blood flow oc-
curred in both hypotensive and normotensive animals [61].
Using intravital microscopy in a rodent model of cecal
ligation and puncture, Piper et al. demonstrated that similar
microcirculatory alterations occurred within skeletal muscles
[62]. The increased proportion of non-perfused capillaries
was associated with a decrease in capillary-venular oxygen
saturation of hemoglobin and an increased capillary oxygen
extraction, as assessed by spectrophotometric functional im-
aging system [63]. As such, microvascular alterations have
been advocated as one of the main determinants in the
pathogenesis of sepsis-related organ dysfunction through
multiple mechanisms, including endothelial dysfunction, im-
paired inter-cellular communication, altered glycocalyx, ad-
hesion and rolling of white blood cells and platelets, and
altered red blood cell deformability [60].
The evaluation of microcirculation in human path-
ology started only later, when the side-stream dark field
(SDF) imaging technique became available at the bed-
side [59]. Almost ten years ago, altered microcirculatory
perfusion was thus demonstrated in patients with severe
sepsis and septic shock when compared to healthy
volunteers and other non-septic critically ill patients.
Sepsis-induced microvascular alterations were assessed
in the sublingual area and were characterized by highly
heterogeneous flow and decreased capillary density with
increased numbers of stopped-flow and intermittent-
flow capillaries (Figure 1) [64]. More severe and
prolonged impairment in microcirculation was observed
in non-survivors [64-66]. Importantly, these alterations
could be reversed by therapeutic interventions such as
early fluid loading or intravenous administration
of nitroglycerin, dobutamine, or activated protein C
[67-70]. In addition, topical application of acetylcholine
could restore normal microvascular perfusion, suggest-
ing that thrombus formation into the capillaries was not
an essential pathophysiological mechanism involved in
these alterations [64].
However, most human studies only evaluated the
sublingual area that may not fully encompass micro-
vascular flow or changes in tissue oxygenation and me-
tabolism within organs. Recent experimental studies
have contributed to better understand the role of micro-
circulation in organ dysfunction during sepsis. In a
porcine model of cholangitis-induced septic shock,
Verdant et al. showed that severity and time course of
A B
Figure 1 Sublingual microcirculation in a healthy volunteer (A) and in a patient with septic shock (B). The density of small vessels is significantly
reduced during septic shock along with areas of different capillary density, the so-called microvascular heterogeneity.
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sublingual areas, suggesting that this latter region would
be appropriate to monitor systemic microcirculatory al-
terations [71]. Microcirculation was altered even in the
brain cortex during experimental sepsis and such changes
were independent from systemic hemodynamics [72].
Also, impaired cerebral microcirculation was associated
with a progressive reduction in brain oxygenation and, in
association with the development of severe hypotension,
was responsible for anaerobic metabolism [73]. Impair-
ment in microcirculation has also been observed in the
liver of septic rats and was improved by hemodynamic
resuscitation with crystalloid solutions, but not with
gelatines [74]. Interestingly, sepsis did not alter renal
cortical microcirculation in the early phase, while nor-
epinephrine induced renal vasoconstriction [75].
Developments in the monitoring of the microcirculation
illustrate how sophisticated technological tools may improve
our comprehension of pathophysiology, as well as their
limits to implementation into routine clinical practice.
Altogether, the aforementioned experimental findings clearly
demonstrated that microvascular dysfunction occurs during
sepsis in several peripheral organs. Given the heterogeneous
aspect of microcirculatory perfusion and the mechanisms
involved in the development of such dysfunctions, it is un-
likely that classical interventions aimed to restore global
hemodynamics might result in significant improvement in
microvascular flow. Nevertheless, we are still lacking some
appropriate devices for clinical settings, which should ideally
combine assessment of microcirculation and tissue oxygen-
ation. Future research should be directed towards improve-
ment in technologies that may increase the accuracy of
microcirculatory assessment in septic patients. Most import-
antly, it remains unknown whether assessment of microcir-
culation and changes induced by therapeutic interventions
may lead to improved management of critically ill patients.
A number of questions remain to be supported by robust
clinical and experimental data, including the type of thera-
peutic interventions and their optimal timing after
hemodynamic stabilization, and the relevant target goalsin capillary flow or tissue oxygenation that should then be
achieved.
Conclusions
Benefits and usefulness of translational research?
From a clinical point of view, translational research has
produced contrasted results in critical care medicine. It
clearly offered major advances in the understanding of the
pathophysiology of sepsis, and animal models have under-
scored the importance of early antibiotic treatment and
aggressive resuscitation that are now commonly imple-
mented during the so-called golden hours of clinical man-
agement. However, advances in the comprehension of the
immunopathology of sepsis that relied on imperfect ani-
mal models failed to translate into successful innovative
therapeutic approaches in humans. Nevertheless, we
learned important lessons from negative trials, and focus-
ing on a single therapeutic target can now be viewed as
simplistic with respect to the complexity of the immune
response. In order to sustain innovative approaches in
critically ill patients, the French Society of Intensive Care
is committed to promote translational research in critical
care medicine.
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